ModernMedicine Resource Center More Topics

Hot Topics in Prostate Cancer

Prostate Ca: Are more men presenting with metastatic disease?A study reporting an increase in the number of men initially presenting with metastatic prostate cancer has been the source of controversy since its July publication.
Robotic vs. open RP: Experts react to first randomized trialWe spoke to Gerald L. Andriole, MD, Michael Koch, MD, Herbert Lepor, MD, Mani Menon, MD, and Joel Nelson, MD, about the highly anticipated study findings.
Study: PCa genomic test reduces decisional conflictFor men with high-risk pathology at radical prostatectomy, exposure to results of a genomic test that classifies 5-year risk of metastasis reduces decisional conflict, according to findings of a prospective study presented at the American Society of Clinical Oncology annual meeting in Chicago.
Cognitive, mood effects characterized for PCa therapiesAn ongoing phase II trial investigating abiraterone acetate (ZYTIGA) and enzalutamide (XTANDI) as treatment for men with chemotherapy-naïve metastatic castrate-resistant prostate cancer is aiming to characterize the effects of these targeted hormonal therapies on cognition and mood.
Using mpMRI, 27% of men could avoid prostate biopsyMultiparametric magnetic resonance imaging (mpMRI) identifies a significant percentage of men who present with an elevated serum PSA level who may safely avoid prostate biopsy, British researchers report.
Is mpMRI ready for prostate Ca screening?"Avoiding unnecessary biopsies should be a high-priority goal for us all," writes J. Brantley Thrasher, MD.
Midlife PSA levels strongly portend future deadly PCa“It appears that baseline PSA is a lot more predictive than either family history or race alone and should be used to risk stratify screening,” the co-lead author of a recent study tells Urology Times.
Hypofractionated vs. conventional RT: How outcomes, safety compareA recent study comparing 8 weeks of conventional radiation therapy with hypofractionated RT over 4 weeks appears to have practice-changing implications for men with intermediate-risk prostate cancer.
Low concordance with NCCN surveillance guide seenConcordance with National Cancer Comprehensive Network recommendations about follow-up during active surveillance for low-risk prostate cancer is generally low across urology practices in Michigan, reported researchers from the Michigan Urological Surgery Improvement Collaborative at the AUA annual meeting in San Diego.
Adjuvant chemo well tolerated in high-risk PCa patientsA Veterans Administration Cooperative Study investigating chemotherapy after prostatectomy for high-risk prostate cancer was underpowered to show a statistically significant benefit of early adjuvant chemotherapy versus observation as the standard of care in the primary endpoint analysis of progression-free survival.